A summary of announcements/highlights from #AGBT23 (in no particular order):
#AGBT23 cfDNA methylation profiling as a blood biomarker for Congestive Heart Failure. This is from the same team that gave you the @GrailBio Methylation Atlas, now applied to biomarker discovery. genomeweb.com/sequencing/agb…
#AGBT23 Miga on the comparison between PacBio Revio and Oxford @nanopore High Duplex / UltraLong reads. PacBio 21/46 T2T and ONT 24/46 (higher is better). Ultralong reads scaffolding for both (unconfirmed) would mean ONT lead is even bigger.
#AGBT23 Nebula Genomics announces the $175 "Deep genome" offering. The caveat is that it requires a subscription which puts the total up to $450. That's the first sub-$200 genome 30x direct to consumer offering, discounting the subscription.
#AGBT23 Illumina Infinity reads are indeed the Longas "noisy polymerase" method (renamed land-marking). Unconfirmed 5x mark-up in $/Gb compared to short-reads, unconfirmed 5-10kb+ DNA sequence lengths.
#AGBT23 BD Rhapsody, single cell partitioning system, microwell tech, 1 cell + 1 bead/well. Cells lysed, retrieve beads, cDNA synthesis. New HT system, 8 lane cartridge, 267k microwells, 320k cells, partial use of cartridge. 24 plex, scCITE-Seq. Unconfirmed: Celsee tech.
#AGBT23@10xGenomics roadmap includes 5,000-plex RNA probes on Xenium imaging, and allele and Isoform mapping in situ; claim of no upper bound for density of RCA probes in situ.
#AGBT23@10xGenomics, Chromium X/iX single cell updates, 1M > 8M cells/chip, 3', 5'-, ATAC, cell surface proteins. New 'Flex', any sample, cells fixed before analysis, 5x more multiplexing scale, more genes/cell. FFPE data looked better than frozen!
#AGBT23@10xGenomics VisiumHD with CytAssist. Unconfirmed ETA, presumably only internal data.
#AGBT23 Both @CompleteGenomic's and @ElemBio technologies capable of paired-end sequencing of inserts of 2kb and 3kb. Unconfirmed limit of Illumina NovaSeq at ~600bp? Unconfirmed limit of Illumina NextSeq 1000/2000 could be even lower?
#AGBT23@CompleteGenomic's DNBSEQ-T7 pricing model for 3 sequencers and reagent commitment down to $1.5/Gb or $150/genome. Announced DNBSEQ-T20 capable of sequencing 50,000 genomes a year with machine included in the reagents for <$100/genome. linkedin.com/pulse/complete…
This adds to the list of NGS offerings, nicely summarized by @LAbizar pre-#AGBT23
And final highlight, first known interaction in the world between Flo-Rida and genomicists. Unconfirmed: there will be a new music video recorded where Flo-Rida entourage is all from genomics community.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
The world of Next-Generation Sequencing (NGS) post-#AGBT23: 1) Some will say that $ILMN Illumina is sleep-walking into a cliff: the company has been dominating the field with 80-90%+ of the market-share, but they are unable to retain their technological advantage to competitors:
- Illumina doesn't have the most affordable $/Gb platform anymore, currently at $3.2/Gb, and $2/Gb in H2 2023, but others are already at $2/Gb, $1.5/Gb and will be at $1/Gb in Q3 2023.
- Illumina doesn't have the longest read technology, or anything near the competition in terms of read length times $/Gb. Oxford @nanopore is unmatched with their ultra-long read technology and is nearing $10/Gb Q30+ performance, as is PacBio on 15-10Kb reads.
In #NextGenerationProteomics news, today we cover the basics of Proximity ligation assay (PLA) technology, also known as proximity barcoding assay technology, which is a method for detecting protein-protein interactions in cells or tissues.
The assay is based on the principle of ligating two probes (such as antibodies) that are in close proximity to each other, typically within a few nanometers. The ligation reaction produces a circular DNA molecule that is amplified by polymerase chain reaction (PCR) and
can be detected by sequencing or by fluorescence-based microarray readouts. The technology allows for the quantification of specific protein interactions in complex biological samples and can be used for a variety of applications, including drug discovery,
#AGBT23 More details on the $ILMN Illumina Infinity reads technology from Alex Aravanis (post from LinkedIn).
Also first data shared on XLEAP-SBS chemistry for the NextSeq 1000/2000 instruments. Not sure why would anyone buy one of these instruments given the alternatives from @ElemBio and @CompleteGenomic 's G400.
First shipment on NovaSeq X: if Illumina can beat the competition at anything in the next few months, it'll be on manufacturing and deployment of the NovaSeq X.
Given all the talk of $100 genomes and tens of thousands of genomes being sequenced per year on a single instrument, the question arises: how many of these sequencing factories are we going to see? how many genome equivalents do we need capacity for?
Taking the 50,000 genomes a year mark as a starting number, and considering we have 140 million new-borns a year, we would need 2,800 DNBSEQ T20 factories distributed around the world only to keep up with the new-born human population.
If we consider that about 10% of the world population is older than 65 years, that's 788 million people. If we rounded up to 1 billion people needing cancer screening via liquid biopsy, and estimated the sequencing needed to be 1/10th of a human genome equivalent, then
In #NextGenerationSequencing, @CompleteGenomic's new of the <$100/genome with their DNBSEQ T20 available from Q3 2023, and their T7x3 $130/genome pricing, we now have 3 companies that have hit the $200/genome mark with announcements: @ElemBio $ILMN Illumina and Complete Genomics.
Both $ILMN Illumina and @CompleteGenomic's will hit the $200/genome and <$100/genome mark in the second half of 2023, but @ElemBio Element Bio AVITIx3 and Complete Genomics T7x3 pricing models are *now* available at $200/genome and $130/genome respectively.
Also @UltimaGenomics is working on their U100 instrument aiming at $100/genome, and had several announcements of partnerships with library prep providers at #AGBT23.
In #JPM2023, $NAUT Nautilus Bio didn't make their slides available, but they have a slide deck from an investor meeting in December 2022. They intend to launch their Proteome Analysis Platform in Mid-2024.
They see a market opportunity of $25B, where 50% would be BioPharma customers, and 20% Academic and Research.
One of the biggest piece of news is that $NAUT Nautilus Bio recently partnered with Abcam to enhance their affinity reagent development program.